
Medicare drug price negotiations lowered out-of-pocket costs for some beneficiaries, but those reaching the annual Part D cap saw no direct savings.
The American Journal of Managed Care
over 25 years ago
Does the HEDIS Asthma Measure Go Far Enough?over 25 years ago
Rheumatoid Arthritis: Guidelines for Emerging Therapies





